About us

Driven by Curiosity. Powered by Innovation.

Because better research models lead to better outcomes — for patients, for science, and for a more responsible future in biomedical innovation.

Innovation starts with people – meet the team behind VitrofluidiX.

Learn more

Our Mission

Reimagining research for a more ethical tomorrow.

Our mission is to enable more ethical, accurate, and human-relevant science by replacing outdated models with cutting-edge organ-on-a-chip technology. We believe that the next generation of medical breakthroughs shouldn’t rely on animal testing or oversimplified cell cultures. Instead, we provide tools that bring research closer to the real complexity of the human body.

Through our integrated VitroFlow platform, we empower scientists, biotech teams, and pharmaceutical innovators to generate reproducible, automated, and physiologically meaningful data — accelerating discovery while reducing risk and resource waste.

We exist to support those who dare to challenge convention in the life sciences.

Because better models mean better outcomes — for patients, for science, and for society.

Our Story

Key moments on the road to human-centered research.

VitrofluidiX began with a bold question: “What if we could recreate human biology in the lab — without relying on animals?”

Since then, we’ve transformed that question into a mission-driven startup, a functional product, and a growing network of scientific collaborators. Here’s a look at our key milestones, achievements, and the people behind the progress.

2018

The Spark

While designing a custom microfluidic chip, the idea for VitrofluidiX was born. During the search for a device that could reliably supply the chip, it became clear: such a system didn’t exist. This gap marked the starting point for developing our all-in-one solution for accessible Organ-on-a-Chip experiments.

2023

First Working Prototype

The first functional version of the VitroFlow.Bio system (V0.1) is built. At the same time, the core team forms around a shared vision: to make organ-on-a-chip technology more accessible, adaptive, and integrated.

2024

From Lab to Market

A first fully functional MVP is developed and tested with first pilot users (V1.0). VitrofluidiX is officially founded and begins its transition from research-driven development to professional operations and product readiness.

2025

Preparations for Launch

The first financing round is successfully closed. Based on user feedback, the team builds now VitroFlow.Bio V2.2 – the market-ready version. A European patent is filed to protect the core technology.

Team

Behind every new idea
is a dedicated team

Carlotta Altringer

CEO

Carlotta Altringer is the CEO and co-founder of VitrofluidiX. With a B.Sc. in Biology from the University of Cologne and an upcoming Executive MBA at CBS, she combines a scientific background with business understanding. Her research has appeared in Current Biology and Cardiovascular Research, and she led the company’s successful pre-seed funding round. She brings together academic experience and entrepreneurial commitment.

David Günter

CSO

David Günter, Chief Scientific Officer and project initiator, also holds a B.Sc. in Biology from the University of Cologne. With a strong foundation in mechanics, bioengineering and theoretical biology, he has been honored with the DGP Poster Award and recognized as a winner of Jugend forscht. As a biotech-tech hybrid, David contributes hands-on skills in microfluidics, Arduino and CAD/CAM, making him a driving force behind VitrofluidiX’s technical innovation.

Dr. Finn Rieken

Business Development / Marketing

Dr. Finn Rieken is Chief Commercial Officer. He holds an M.Sc. in Molecular Biotechnology from TUM and earned his PhD at ETH Zurich. Finn brings strategic business expertise from his previous roles as a strategy consultant at goetzpartners and Clariant. He also gained research experience at Harvard University. With a strong background in business development and venture capital, he plays a key role in shaping the company’s growth strategy.

Peter Fuß

Production

Peter Fuß leads production and hardware development. A certified industrial mechanic with more than 30 years of experience, Peter is an expert in electronics, mechanics, and custom lab hardware. His in-depth knowledge of CNC, PCB design, and CAD systems makes him essential to the precision and reliability of our manufacturing processes.

Dr. Sven Binder

Finance

Dr. Sven Binder oversees finance and operations. He holds a PhD from the Karlsruhe Institute of Technology (KIT) and both M.A. and B.A. degrees in Business. He has led clinical digitalization at Sana and served as a commercial director and university lecturer. Certified in PRINCE2 and Scrum, Sven combines strategic insight with operational excellence, ensuring the smooth financial and legal management of the company.

Caspar Kneer

Product Development

Caspar Kneer is responsible for engineering at VitrofluidiX. He holds an M.Sc. in Applied Physics and conducted doctoral research in optical plant physiology. He previously worked at the Fraunhofer Institute and Forschungszentrum Jülich. As a freelance engineer, Caspar specializes in sensor development, systems integration, and rapid prototyping, bringing extensive technical expertise to the team.